Neoadjuvant and adjuvant systemic treatment for hepatocellular carcinoma

Imagem de Miniatura
Arquivos
art_MATHIAS-MACHADO_Neoadjuvant_and_adjuvant_systemic_treatment_for_hepatocellular_carcinoma_2021.PDF (395.94 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
OAE PUBLISHING INC
Autores
Citação
HEPATOMA RESEARCH, v.7, article ID 67, 12p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Hepatocellular carcinoma (HCC) is a highly lethal malignancy, and few patients are candidates for curative-intended therapies. The mainstay of curative treatment in HCC is surgical resection, ablation, and transplantation. However, rates of recurrence are high, and there is no established approach to reduce the risk of recurrence and mortality. We discuss the available data and current landscape of (neo)adjuvant therapies aimed at decreasing recurrence risk and improving overall survival, including liver-directed therapies, tyrosine kinase inhibitors, and immunotherapy. Neoadjuvant strategies aimed at downstaging advanced HCC to enable local treatment and minimize the risk of recurrence using novel agents are also a topic of interest in current research. The improvements achieved in the advanced stages with immune-checkpoint inhibitors are priming ongoing trials that address potential future directions for both adjuvant and neoadjuvant strategies that may change the treatment paradigm of HCC in the near future.
Palavras-chave
Liver neoplasm, hepatocellular carcinoma, neoadjuvant treatment, adjuvant treatment, immunotherapy
URI
https://observatorio.fm.usp.br/handle/OPI/57645
Referências
  1. [Anonymous], 2021, Cancer Res, V81
  2. Brown ZJ, 2019, HEPATOLOGY, V70, P1437, DOI 10.1002/hep.30633
  3. Bruix J, 2019, NAT REV GASTRO HEPAT, V16, P617, DOI 10.1038/s41575-019-0179-x
  4. Bruix J, 2015, LANCET ONCOL, V16, P1344, DOI 10.1016/S1470-2045(15)00198-9
  5. Chen DS, 2018, CANCER J, V24, P193, DOI 10.1097/PPO.0000000000000327
  6. Chen KY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057397
  7. Chen Q, 2018, GUT, V67, P2006, DOI 10.1136/gutjnl-2018-315983
  8. Choi JH, 2017, ONCOTARGET, V8, P22903, DOI 10.18632/oncotarget.14248
  9. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, 2019, J Hepatol, V70, P817, DOI 10.1016/j.jhep.2019.01.020
  10. Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745
  11. Gaba RC, 2009, ANN SURG ONCOL, V16, P1587, DOI 10.1245/s10434-009-0454-0
  12. Gabrielson A, 2016, CANCER IMMUNOL RES, V4, P419, DOI 10.1158/2326-6066.CIR-15-0110
  13. Hasegawa K, 2013, J HEPATOL, V58, P724, DOI 10.1016/j.jhep.2012.11.009
  14. Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086
  15. Jiaqiang, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0814-7
  16. Kallini JR, 2016, ADV THER, V33, P699, DOI 10.1007/s12325-016-0324-7
  17. Kuang M, 2004, CLIN CANCER RES, V10, P1574, DOI 10.1158/1078-0432.CCR-03-0071
  18. Kudo M, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.4070
  19. Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1
  20. Lee JH, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1328335
  21. Lei JY, 2014, ANN HEPATOL, V13, P394, DOI 10.1016/S1665-2681(19)30846-4
  22. Lencioni R, 2013, SEMIN INTERVENT RAD, V30, P3, DOI 10.1055/s-0033-1333648
  23. Li SH, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.4008
  24. Liu J, 2015, THORAC CANCER, V6, P561, DOI 10.1111/1759-7714.12270
  25. Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
  26. MONDEN M, 1989, CANCER CHEMOTH PHARM, V23, pS90, DOI 10.1007/BF00647249
  27. Okajima W, 2017, WORLD J GASTROENTERO, V23, P5650, DOI 10.3748/wjg.v23.i31.5650
  28. Ouyang LM, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-2
  29. Pinato DJ, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08033-x
  30. Portolani N, 2006, ANN SURG, V243, P229, DOI 10.1097/01.sla.0000197706.21803.a1
  31. Qi XS, 2015, ONCOTARGET, V6, P36838, DOI 10.18632/oncotarget.5426
  32. Salem R, 2021, HEPATOLOGY, V74, P2342, DOI 10.1002/hep.31819
  33. Schwarz RE, 2010, HPB, V12, P313, DOI 10.1111/j.1477-2574.2010.00183.x
  34. Sun HC, 2006, J CANCER RES CLIN, V132, P458, DOI 10.1007/s00432-006-0091-y
  35. Takayama T, 2000, LANCET, V356, P802, DOI 10.1016/S0140-6736(00)02654-4
  36. von Felden J, 2021, ONCOGENE, V40, P140, DOI 10.1038/s41388-020-01519-1
  37. Wang Z, 2018, CLIN CANCER RES, V24, P2074, DOI 10.1158/1078-0432.CCR-17-2899
  38. Wei W, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0331-y
  39. Xia Y, 2010, ANN SURG ONCOL, V17, P3137, DOI 10.1245/s10434-010-1148-3
  40. Yau T, 2020, JAMA ONCOL, V6, DOI 10.1001/jamaoncol.2020.4564
  41. Yin JH, 2013, J CLIN ONCOL, V31, P3647, DOI 10.1200/JCO.2012.48.5896
  42. Zhai XF, 2018, CANCER-AM CANCER SOC, V124, P2161, DOI 10.1002/cncr.30915
  43. Zhang W, 2014, MOL CLIN ONCOL, V2, P1125, DOI 10.3892/mco.2014.386
  44. Zhang YQ, 2016, ONCOLOGIST, V21, P1442, DOI 10.1634/theoncologist.2016-0094
  45. Zhang Zhijian, 1999, Zhonghua Zhongliu Zazhi, V21, P214
  46. Zhu AX, 2018, LANCET ONCOL, V19, P940, DOI 10.1016/S1470-2045(18)30351-6

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - ODS/03